<DOC>
	<DOCNO>NCT02207790</DOCNO>
	<brief_summary>This study primarily design bridge pharmacokinetics ( PK ) safety data E2609 Japanese subject non-Japanese ( ie , white ) subject . To bridge PK characteristic , propose study include cohort white subject treat comparison cohort Japanese subject treat dose . This comparison serve key PK bridge assess ethnic factor may contribute difference plasma concentration . Pharmacokinetic assessment propose study include confirmation dose proportionality Japanese subject . This study also evaluate safety tolerability Japanese subject .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics E2609 Healthy Adult Male Japanese White Subjects</brief_title>
	<detailed_description />
	<criteria>The subject must meet follow criterion order include study . Japanese Subjects Only : 1 . Birth Japan Japanese parent grandparent Japanese descent 2 . Have live outside Japan le 5 year 3 . Lifestyle , include diet , change significantly since leave Japan White Subjects Only : 4 . A person origins original people Europe , Middle East , North Africa base document subject selfreport All Subjects : 5 . Healthy male , 30 60 year inclusive , time informed consent 6 . BMI 18 32 kg/m2 inclusive Screening 7 . Subjects must successful vasectomy ( confirm azoospermia ) female partner must childbearing potential must practice highly effective contraception ( i.e . condom plus spermicide , condom plus diaphragm spermicide , intrauterine device start least one menstrual cycle start study drug [ ] ) throughout study period 30 day study drug discontinuation . No sperm donation allow study period 30 day study drug discontinuation . Subjects meet follow criterion exclude study : 1 . Any history seizure epilepsy 2 . Any medical condition , opinion investigator high risk seizure 3 . Any history cerebrovascular disease 4 . A history prolong QTc interval 5 . Any clinically significant ECG abnormalities 6 . History risk factor torsade de pointes use medication prolong QT/QTc interval 7 . Heart rate le 50 great 100 beats/min 8 . History ischemic heart disease 9 . Persistent systolic blood pressure ( BP ) great 140 mmHg less 90 mmHg diastolic BP great 90 mmHg less 60 mmHg 10 . Left bundle branch block 11 . Evidence clinically significant disease 12 . Any laboratory abnormality consider clinically significant 13 . Clinically significant illness require medical treatment 14 . Any history abdominal surgery may affect study drug 15 . Hypersensitivity study drug 16 . Known HIV positive 17 . Active viral hepatitis 18 . History drug alcohol dependency abuse within approximately last 2 year 19 . Scheduled surgery study 20 . Engagement strenuous exercise within 2 week dose ( eg , marathon runner , weight lifter ) 21 . Currently enrol another clinical trial use investigational drug device within 30 day inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Clinical Trial , Phase I</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>